$AXSM
Axsome Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000095017021003466 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $18.83M $20.23M $16.34M
YoY Change 81.72% 219.54% 125.75%
% of Gross Profit
Research & Development $13.78M $13.18M $14.50M
YoY Change -20.71% -10.92% 37.56%
% of Gross Profit
Depreciation & Amortization $31.04K $27.23K $8.080K
YoY Change 172.3%
% of Gross Profit
Operating Expenses $32.61M $33.41M $30.85M
YoY Change 17.53% 58.13% 73.51%
Operating Profit -$33.41M
YoY Change 58.13%
Interest Expense -$1.368M -$1.476M -$1.437M
YoY Change -6.93% 168.28% 161.19%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$33.98M -$34.88M -$32.28M
YoY Change 16.52% 52.19% 76.13%
Income Tax
% Of Pretax Income
Net Earnings -$33.98M -$34.88M -$32.28M
YoY Change 16.5% 52.16% 76.16%
Net Earnings / Revenue
Basic Earnings Per Share -$0.93
Diluted Earnings Per Share -$899.6K -$925.7K -$858.7K
COMMON SHARES
Basic Shares Outstanding 37.69M 37.68M
Diluted Shares Outstanding 37.68M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $86.47M $114.6M $141.2M
YoY Change -52.98% -43.37% -25.95%
Cash & Equivalents $86.47M $114.6M
Short-Term Investments
Other Short-Term Assets $45.29K $401.3K $435.8K
YoY Change -54.71% -55.41% 335.8%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $86.52M $115.0M $141.7M
YoY Change -52.99% -43.41% -25.76%
LONG-TERM ASSETS
Property, Plant & Equipment $283.8K $314.9K $1.292M
YoY Change 439.15% 692.28% 4148.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $322.9K $322.9K $317.4K
YoY Change 1.74% 1.74% 126.9%
Total Long-Term Assets $1.267M $1.574M $1.610M
YoY Change -39.94% 340.84% 845.32%
TOTAL ASSETS
Total Short-Term Assets $86.52M $115.0M $141.7M
Total Long-Term Assets $1.267M $1.574M $1.610M
Total Assets $87.79M $116.6M $143.3M
YoY Change -52.84% -42.74% -24.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.15M $13.38M $11.61M
YoY Change -2.63% 18.26% 24.02%
Accrued Expenses $9.916M $11.33M $11.25M
YoY Change 0.16% 25.84% 58.47%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.07M $24.71M $22.86M
YoY Change -1.59% 21.46% -0.6%
LONG-TERM LIABILITIES
Long-Term Debt $49.09M $49.17M $48.88M
YoY Change 1.59% 2.39% 255.66%
Other Long-Term Liabilities $0.00 $0.00 $81.86K
YoY Change -100.0%
Total Long-Term Liabilities $49.09M $49.17M $48.88M
YoY Change 1.59% 2.39% 255.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.07M $24.71M $22.86M
Total Long-Term Liabilities $49.09M $49.17M $48.88M
Total Liabilities $72.15M $73.88M $71.83M
YoY Change -0.26% 8.06% 95.47%
SHAREHOLDERS EQUITY
Retained Earnings -$409.2M -$375.2M -$340.3M
YoY Change 46.77% 50.32% 50.11%
Common Stock $424.8M $417.9M
YoY Change 8.21% 11195742.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.63M $42.72M $71.44M
YoY Change
Total Liabilities & Shareholders Equity $87.79M $116.6M $143.3M
YoY Change -52.84% -42.74% -24.99%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$33.98M -$34.88M -$32.28M
YoY Change 16.5% 52.16% 76.16%
Depreciation, Depletion And Amortization $31.04K $27.23K $8.080K
YoY Change 172.3%
Cash From Operating Activities -$28.84M -$26.78M -$25.39M
YoY Change 40.27% 70.22% 34.33%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$258.7K -$18.87K
YoY Change -100.0% 1193.4%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$258.7K -$18.87K
YoY Change -100.0% 1193.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 690.5K 438.7K 1.971M
YoY Change -66.96% -98.4% -83.94%
NET CHANGE
Cash From Operating Activities -28.84M -26.78M -25.39M
Cash From Investing Activities 0.000 -258.7K -18.87K
Cash From Financing Activities 690.5K 438.7K 1.971M
Net Change In Cash -28.15M -26.60M -23.44M
YoY Change 52.24% -327.9% 253.5%
FREE CASH FLOW
Cash From Operating Activities -$28.84M -$26.78M -$25.39M
Capital Expenditures $0.00 -$258.7K -$18.87K
Free Cash Flow -$28.84M -$26.52M -$25.37M
YoY Change 40.41% 68.79% 34.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001579428
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity File Number
EntityFileNumber
001-37635
dei Entity Registrant Name
EntityRegistrantName
AXSOME THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4241907
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address Address Line1
EntityAddressAddressLine1
22 Cortlandt Street
dei Entity Address Address Line2
EntityAddressAddressLine2
16th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10007
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
332-3241
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
dei Trading Symbol
TradingSymbol
AXSM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37691733
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114622893
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
183876453
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
401302
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
148373
CY2021Q3 us-gaap Assets Current
AssetsCurrent
115024195
CY2020Q4 us-gaap Assets Current
AssetsCurrent
184024826
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
314891
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52647
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
936526
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1739475
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
322910
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
317375
CY2021Q3 us-gaap Assets
Assets
116598522
CY2020Q4 us-gaap Assets
Assets
186134323
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
13381681
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13504022
CY2021Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10445172
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8713249
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
880116
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1220587
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
24706969
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23437858
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49173709
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.98
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48321848
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
581708
CY2021Q3 us-gaap Liabilities
Liabilities
73880678
CY2020Q4 us-gaap Liabilities
Liabilities
72341414
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37687883
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37687883
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37374088
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37374088
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
3769
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3737
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
417937024
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
392585265
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-375222949
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278796093
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
42717844
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113792909
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116598522
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
186134323
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13180258
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14795493
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44279272
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
52859850
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20226884
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6331308
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
47819618
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18537242
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
33407142
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
21126801
us-gaap Operating Expenses
OperatingExpenses
92098890
us-gaap Operating Expenses
OperatingExpenses
71397092
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-33407142
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-21126801
us-gaap Operating Income Loss
OperatingIncomeLoss
-92098890
us-gaap Operating Income Loss
OperatingIncomeLoss
-71397092
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.57
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-1475535
CY2020Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-551002
us-gaap Investment Income Net
InvestmentIncomeNet
-4327966
us-gaap Investment Income Net
InvestmentIncomeNet
-1091849
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1247012
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1247012
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-34882677
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-22924815
us-gaap Net Income Loss
NetIncomeLoss
-96426856
us-gaap Net Income Loss
NetIncomeLoss
-73735953
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37680966
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37311726
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37569416
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37158513
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
178722389
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2133530
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
629756
CY2020Q1 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
7155337
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-32484146
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
156156866
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4148025
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
190409
CY2020Q2 axsm Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3
CY2020Q2 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
12074999
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-18326992
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
154243310
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2868818
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
190226
CY2020Q3 axsm Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3
CY2020Q3 axsm Warrants Issued During Period Debt Financing
WarrantsIssuedDuringPeriodDebtFinancing
884216
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-22924815
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
135261758
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113792909
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3731097
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1913299
CY2021Q1 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
6115864
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-29259970
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
96293199
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5456242
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
958895
CY2021Q2 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
1096503
CY2021Q2 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
84010
axsm Noncash Research And Development Expense
NoncashResearchAndDevelopmentExpense
7155337
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
851862
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
491009
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
802949
axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-922179
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1922716
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79385245
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-57903052
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1247012
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
307549
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25604
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-307549
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25604
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7212367
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12074999
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-32284209
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
71436620
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5725217
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
438683
CY2021Q3 axsm Stock Vested During Period Value Restricted Common Stock Award
StockVestedDuringPeriodValueRestrictedCommonStockAward
1
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-34882677
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
42717844
us-gaap Profit Loss
ProfitLoss
-96426856
us-gaap Profit Loss
ProfitLoss
-73735953
us-gaap Share Based Compensation
ShareBasedCompensation
14912556
us-gaap Share Based Compensation
ShareBasedCompensation
9150373
us-gaap Depreciation
Depreciation
45305
us-gaap Depreciation
Depreciation
16482
axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
252929
axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
498897
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5535
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
177500
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-122341
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
371801
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1731923
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
50000000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1102609
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
21660000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3310877
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1010391
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
84010
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10439234
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
40322781
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-69253560
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17605875
CY2020Q4 us-gaap Cash
Cash
183876453
CY2019Q4 us-gaap Cash
Cash
219966167
CY2021Q3 us-gaap Cash
Cash
114622893
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1169167
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3469375
CY2020Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
421004
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1179338
CY2021Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
155226
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
448096
CY2020Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
87425
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
325453
CY2020Q3 us-gaap Cash
Cash
202360292
us-gaap Interest Paid Net
InterestPaidNet
3482083
us-gaap Interest Paid Net
InterestPaidNet
1179337
axsm Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
884216
axsm Common Stock Issued In Connection With License Agreement
CommonStockIssuedInConnectionWithLicenseAgreement
8000000
CY2021Q3 axsm Number Of Late Stage Product Candidates
NumberOfLateStageProductCandidates
5
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-375200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock‑based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; and the recoverability of the Company’s net deferred tax assets and related valuation allowance.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
114600000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At September 30, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">, the majority of the Company’s cash was held by </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.</span></p>
CY2021Q3 axsm Number Of Financial Institutions Holding Deposits
NumberOfFinancialInstitutionsHoldingDeposits
1
us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1962691
CY2020Q4 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4293522
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3056345
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2870261
CY2021Q3 axsm Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
5044886
CY2020Q4 axsm Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
1155508
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
381250
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
393958
CY2021Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
10445172
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8713249
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2021Q3 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
600009
CY2020Q4 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
151912
CY2021Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1426300
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1830064
CY2021Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49173709
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48321848
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
12193153
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
19761468
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
18045379
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-34882677
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-22924815
us-gaap Net Income Loss
NetIncomeLoss
-96426856
us-gaap Net Income Loss
NetIncomeLoss
-73735953
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37680966
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37311726
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37569416
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37158513
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.57
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.98
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4912384
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4081318
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
286923
us-gaap Operating Lease Cost
OperatingLeaseCost
860769
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
210854
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
41.68
axsm Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
983
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
79.19
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4594842
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.90
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
630000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
900000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
19884
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
880116
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M12D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
184602602
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
270000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
axsm Equity Instrument Voting Rights Per Share
EquityInstrumentVotingRightsPerShare
1
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3725648
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1279152
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
62.09
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
198121
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
16.71
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4588673
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
27.94
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
184194454
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2784567
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
149261931
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
45.81
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
60400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M12D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
6169
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5725217
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2868818
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14912556
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9150373
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43
axsm Warrants Issued In Period
WarrantsIssuedInPeriod
0
axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
0
axsm Warrants Exercised In Period
WarrantsExercisedInPeriod
0
axsm Warrants Exercised In Period Weighted Average Exercise Price
WarrantsExercisedInPeriodWeightedAverageExercisePrice
0
CY2021Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43

Files In Submission

Name View Source Status
0000950170-21-003466-index-headers.html Edgar Link pending
0000950170-21-003466-index.html Edgar Link pending
0000950170-21-003466.txt Edgar Link pending
0000950170-21-003466-xbrl.zip Edgar Link pending
axsm-20210930.htm Edgar Link pending
axsm-20210930.xsd Edgar Link pending
axsm-20210930_cal.xml Edgar Link unprocessable
axsm-20210930_def.xml Edgar Link unprocessable
axsm-20210930_htm.xml Edgar Link completed
axsm-20210930_lab.xml Edgar Link unprocessable
axsm-20210930_pre.xml Edgar Link unprocessable
axsm-ex10_1.htm Edgar Link pending
axsm-ex31_1.htm Edgar Link pending
axsm-ex31_2.htm Edgar Link pending
axsm-ex32_1.htm Edgar Link pending
axsm-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending